CoQ10's Problem Isn't the Evidence. It's Getting Through the Skin.

The molecule is not in doubt

Start with what is genuinely established, because CoQ10 is unusual among cosmetic actives in having a well-characterised job in human biology before anyone thought to put it in a cream.

Coenzyme Q10 — ubiquinone — sits in the inner mitochondrial membrane and shuttles electrons between complexes of the respiratory chain. Without it, oxidative phosphorylation does not proceed and cells do not make ATP efficiently. It is not a fringe molecule; it is infrastructure.

It has a second job that is the reason it interests skincare. In its reduced form it acts as a lipid-soluble antioxidant, and it is one of the few endogenous antioxidants positioned inside membranes, where it can interrupt lipid peroxidation chain reactions at the point they occur. Water-soluble antioxidants cannot reach there.

And the premise that motivates topical use is also real: CoQ10 levels in skin decline with age and under external stress including ultraviolet exposure. Reviews of the area describe exactly that trajectory, and connect it to the broader picture of mitochondrial decline in ageing skin, which is an active research field in its own right.

So the setup is unusually strong. A molecule with a defined function, a documented age-related decline, and a plausible mechanism for why replacing it might matter. Almost every problem with topical CoQ10 arrives after this point, and none of them is about whether the biology is real.

Three physical properties that make this hard

The obstacles are physical, and they are worth naming individually because each constrains a different part of the formulation.

Size. The rough working rule in dermal delivery is that passive penetration through intact stratum corneum falls off sharply above around 500 daltons. CoQ10's molecular weight is well over 800. That figure is a heuristic rather than a wall, and plenty of larger molecules do useful things at the surface — but for a molecule whose proposed action is inside cells in the viable epidermis and dermis, being that far above the threshold is a serious problem rather than a footnote.

Lipophilicity. CoQ10 is extremely fat-soluble, with a long isoprenoid tail. Intense lipophilicity is not straightforwardly good for penetration; it means the molecule partitions readily into the lipid-rich stratum corneum and then stays there, reluctant to move on into the more aqueous environment beneath. Reviews describe increased CoQ10 in the stratum corneum after application, with the deeper picture harder to establish. A molecule that loves the barrier is a molecule that accumulates in the barrier.

Colour and stability. CoQ10 is a vivid orange-yellow. That is a hard aesthetic ceiling: past a certain concentration your cream is orange, and consumers reject orange cream. It also oxidises, so a formula has to protect it — which means antioxidant support, opaque packaging, and often air-restrictive dispensing. ↗Vitamin E frequently appears alongside it partly for that reason, regenerating the reduced form and slowing degradation.

Put those together and the constraint is clear. You cannot simply solve delivery by adding more, because colour caps the concentration. You cannot rely on lipophilicity to carry it deeper, because lipophilicity is part of why it stalls. And whatever you do, the material has to survive the jar. ↗Our CoQ10 page carries the evidence grading against these constraints.

The derivatives are answers to the delivery problem, not new discoveries

Once you see the problem as delivery, the ingredient list of this category starts making sense — because most of what appears alongside or instead of ubiquinone is an attempt to get around one of those three properties.

Ubiquinol is CoQ10 in its reduced form, which is the antioxidant-active state. Using it directly means the skin does not have to reduce ubiquinone first. It is also less stable, oxidising back readily, so it demands more of the formulation than it gives back — a trade rather than an upgrade.

Idebenone is a synthetic analogue with a much shorter side chain, which makes it smaller, less lipophilic and more soluble. It was developed as a pharmaceutical before it was a cosmetic ingredient, and it has its own clinical assessment in photodamaged skin at low percentages. It is the clearest example of the pattern: when a molecule's problem is its tail, shorten the tail.

Vehicle engineering is the third route, and probably the most consequential. Liposomes, phospholipid vesicles, nanoemulsions and similar systems exist to carry a lipophilic cargo past the stratum corneum rather than into it. Work on CoQ10 phospholipid vesicular formulations has looked at exactly this, assessing ex vivo permeation alongside clinical appraisal — which is the right experimental shape, because it measures whether the material moved before asking whether it helped.

The practical inference for a shopper is unusual and rather useful: with CoQ10, the interesting information is not the percentage. It is whether the formulator did anything about delivery at all. A cream listing ubiquinone low on the panel with no vesicular system, no antioxidant partner and a clear jar has told you it is present rather than that it is arriving. Running the panel through our ingredient decoder will show you whether the supporting cast is there.

The clinical evidence, read with its authorship in view

The human evidence for topical CoQ10 exists, is generally favourable, and is smaller and more conflicted than the marketing implies.

A 2024 review in the Journal of Clinical and Aesthetic Dermatology gathered the modern literature and concluded that topical application replenishes cellular CoQ10 levels, supports energy homeostasis, provides antioxidant effects, and clinically reduces the depth of cutaneous wrinkles. It reports that in ex vivo and in vivo studies, applied CoQ10 increased levels both at the skin surface and in deeper layers.

That is a positive summary, and here is the thing worth knowing before you weigh it: several of its authors are affiliated with Beiersdorf, a company that markets a CoQ10 skincare line. That is disclosed in the paper's affiliations rather than hidden, and industry-affiliated review authorship is common and not disqualifying. But a review is a set of judgement calls about which studies to include and how to characterise them, and knowing who made those calls is part of reading it. A reader who would flag that arrangement in a supplement study should flag it here.

The broader literature is thinner than that review's confidence suggests. A systematic review of over-the-counter antiageing agents places CoQ10 among the plausible-but-modestly-supported group rather than alongside retinoids. Idebenone has its own small clinical assessment in photodamage. The vesicular formulation work is early and specific.

So the honest position: topical CoQ10 probably does something modest as an antioxidant, in a well-built formula, over months. It is not in the same evidentiary category as a retinoid or a well-formulated vitamin C, and any product positioning it as a primary anti-ageing active is asking it to carry more than the data supports. ↗The antioxidants overview sets out how the class compares.

Oral versus topical, and where each argument actually lives

CoQ10 has a substantial life as an oral supplement, and the two conversations get mixed up in a way that flatters the topical one.

The oral literature is mostly about things other than skin — cardiovascular endpoints, statin-associated muscle symptoms, mitochondrial disorders, migraine — with a mixed and much-debated record. Whatever one concludes there, it does not transfer. Oral supplementation raises plasma CoQ10; how much of that reaches skin, and whether it changes anything visible, is a separate and much less studied question. Citing the cardiology literature to support a face cream is a category error, and it happens constantly.

Meanwhile the topical argument has a specific advantage that gets underused: local delivery of an antioxidant to the tissue receiving the oxidative insult is a coherent strategy, because ultraviolet exposure generates reactive species in the skin and nowhere else. That is a better rationale than systemic dosing, provided the delivery problem is solved.

Which leads to the honest ranking for anyone deciding where CoQ10 belongs in a routine.

It is a supporting antioxidant, not a foundation. If your anti-ageing routine does not yet contain daily sun protection and a retinoid you tolerate, adding CoQ10 is optimising the wrong variable — sun protection prevents the damage this molecule is being asked to mop up, and no antioxidant outperforms not being oxidised in the first place.

If those are in place and you want an antioxidant layer, CoQ10 is a reasonable member of that layer, best chosen in a formula that shows evidence of caring about delivery and stability: opaque or air-restrictive packaging, antioxidant partners, and a vehicle doing some work. ↗Nivea Q10 Anti-Wrinkle Power Firming Night Cream is the category's most familiar expression. ↗The INKEY List Q10 Serum is the most accessible. And ↗Dermalogica Phyto Nature Firming Serum alongside ↗Nivea Q10 Replenishing Day Cream pairs it with other actives, which is the more sensible construction — an antioxidant is a team player by definition, since its job is to be consumed protecting something else.

And judge it on the timescale antioxidants actually work on, which is months of consistent use and prevention rather than a visible change you can point at in a fortnight. ↗Our anti-ageing routine puts the order in place; this ingredient belongs somewhere after the first two steps, not instead of them.